Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures

Next Previous
Trial Profile

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Myocardial infarction; Peripheral arterial disorders; Peripheral ischaemia; Stroke; Thrombosis; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VOYAGER PAD
  • Sponsors Bayer; Bayer HealthCare; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine

Most Recent Events

  • 04 Apr 2024 According to a Johnson & Johnson media release, analysis from this trial will be presented at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia.
  • 01 Apr 2024 Methods, design, and initial results of an angiographic core lab from this study published in the Vascular Medicine
  • 14 Nov 2023 According to Janssen media release, results from this trial were presented at the American Heart Association's (AHA) 2023 Scientific Sessions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top